Read by QxMD icon Read

hbv pres

Kai-Wen Li, Anna Kramvis, Shujia Liang, Xiang He, Qin-Yan Chen, Chao Wang, Qing-Li Yang, Li-Ping Hu, Hui-Hua Jia, Zhong-Liao Fang
In the era of combination therapy for human immunodeficiency virus (HIV), liver disease including hepatocellular carcinoma (HCC), are the major causes of death for patients co-infected with hepatitis B virus (HBV) and HIV. However, the mechanisms remain obscure. We aimed to determine whether HCC-related HBV mutations including 1762T/1764A double mutation and pre-S deletions occur more frequently in HBV/HIV co-infected individuals compared to HBV mono-infected individuals. In this study, the basic core promoter (BCP) and the preS/S regions of HBV isolated from 61 pairs of HBV/HIV co-infected and HBV mono-infected participants were analyzed...
October 6, 2016: Virus Research
Carolin Cornelius, Katrin Schöneweis, Fanny Georgi, Milena Weber, Verena Niederberger, Petra Zieglmayer, Katarzyna Niespodziana, Michael Trauner, Harald Hofer, Stephan Urban, Rudolf Valenta
BACKGROUND: We have constructed and clinically evaluated a hypoallergenic vaccine for grass pollen allergy, BM32, which is based on fusion proteins consisting of peptides from the IgE binding sites of the major grass pollen allergens fused to preS (preS1+preS2), a domain of the hepatitis B virus (HBV) large envelope protein which mediates the viral attachment and entry. Aim of this study was the characterization of the HBV-specific immune response induced by vaccination of allergic patients with BM32 and the investigation of the vaccines' potential to protect against infection with HBV...
September 2016: EBioMedicine
Ian Baudi, Sayuki Iijima, Nyasha Chin'ombe, Sekesai Mtapuri-Zinyowera, Shuko Murakami, Masanori Isogawa, Atsuko Hachiya, Yasumasa Iwatani, Yasuhito Tanaka
The objective of this study was to determine the prevalence of co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) and the genetic characteristics of both viruses among pre-HIV-treatment patients in Harare, Zimbabwe. This cross-sectional survey involved 176 remnant plasma samples collected from consenting HIV patients (median age 35 [18-74]) between June and September 2014. HBV seromarkers were determined by high-sensitivity chemiluminescence assays. Molecular evolutionary analyses were conducted on the basal core promoter/precore (BCP/PC) and S regions of HBV, as well as part of the HIV pol region...
July 26, 2016: Journal of Medical Virology
Xiaodong Li, Yaqun Qin, Yan Liu, Fan Li, Hao Liao, Shanshan Lu, Yan Qiao, Dongping Xu, Jin Li
BACKGROUND: The association of hepatitis B virus (HBV) preS1 and preS2 deletions with progressive liver diseases are not fully understood. OBJECTIVE: The study aimed to investigate characteristics of HBV preS deletion in HBV-infected patients with different illness categories. STUDY DESIGN: Total of 539 HBV-infected patients were enrolled in the study, including 146 with chronic hepatitis B (CHB), 111 with HBV-related liver cirrhosis (LC), 146 with HBV-related acute-on-chronic liver failure (ACLF), and 136 with HBV-related hepatocellular carcinoma (HCC)...
September 2016: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
Pia L Seiz, Christina Mohr, Dianna E Wilkinson, John Ziebuhr, Christian G Schüttler, Wolfram H Gerlich, Dieter Glebe
BACKGROUND: HBsAg is the most important marker for laboratory diagnosis of HBV infection. Validation and quality control of HBsAg tests requires International Standards (IS). Recently the 2nd IS was replaced by the 3rd IS. Both IS are made from plasma-derived hepatitis B vaccines, but production and geographical origin are different. OBJECTIVE: Characterization of the HBsAg in the source material (SM) for the 3rd IS and comparison with the 2nd IS and native HBsAg...
September 2016: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
Stefan Seitz, Caroline Iancu, Tassilo Volz, Walter Mier, Maura Dandri, Stephan Urban, Ralf Bartenschlager
Hepatitis B virus (HBV) replication is strictly limited to the liver. Virions attach to hepatocytes through interactions of the viral PreS envelope protein domain with heparan sulfate proteoglycans (HSPGs). However, HSPG is ubiquitously present on many cell types, suggesting that HBV employs mechanisms to avoid attachment at extrahepatic sites. We demonstrate that HBV particles are released from cells in an inactive form with PreS hidden in the interior. These HSPG-non-binding (N-type) particles develop receptor binding competence by translocating PreS across the envelope onto their surface...
July 13, 2016: Cell Host & Microbe
B D Betz-Stablein, A Töpfer, M Littlejohn, L Yuen, D Colledge, V Sozzi, P Angus, A Thompson, P Revill, N Beerenwinkel, N Warner, F Luciani
UNLABELLED: Chronic hepatitis B (CHB) is prevalent worldwide. The infectious agent, hepatitis B virus (HBV), replicates via an RNA intermediate and is error prone, leading to the rapid generation of closely related but not identical viral variants, including those that can escape host immune responses and antiviral treatments. The complexity of CHB can be further enhanced by the presence of HBV variants with large deletions in the genome generated via splicing (spHBV variants). Although spHBV variants are incapable of autonomous replication, their replication is rescued by wild-type HBV...
August 15, 2016: Journal of Virology
Jianhong Chen, Yan Liu, Jun Zhao, Zhihui Xu, Rongjuan Chen, Lanlan Si, Shanshan Lu, Xiaodong Li, Shuai Wang, Kai Zhang, Jin Li, Juqiang Han, Dongping Xu
OBJECTIVE: The impact of hepatitis B virus (HBV) preS/S-gene mutations on occult HBV infection (OBI) is not fully understood. This study characterized multiple novel HBV preS/S-gene mutants obtained from an OBI patient. METHODS: PreS/S-gene mutants were analyzed by clonal sequencing. Viral replication and expression were analyzed by transfecting HBV genomic recombinants into HepG2 cells. RESULTS: Twenty-one preS/S-gene mutants were cloned from four sequential serum samples, including 13 mutants that were not previously documented: (1) sI/T126V+sG145R; (2) preS1 nt 3014-3198 deletion; (3) preS1 nt 3046-3177 deletion; (4) preS1 nt 3046-3177 deletion+s115-116 "INGTST" insertion; (5) preS1 nt 3046-3177 deletion+s115-116 "INGTST" insertion+sG145R; (6) preS1 nt 3115-3123 deletion+sQ129N; (7) preS1 nt 3115-3123 deletion+s126-127 "RPCMNCTI" insertion; (8) s115-116 "INGTST" insertion; (9) s115-116 "INGTST" insertion+sG145R; (10) s126-127 "RPCMNCTI" insertion; (11) preS1 nt 2848-2862 deletion+preS2 initiation codon M→I; (12) s122-123 "KSTGLCK" insertion+sQ129N; and (13) preS2 initiation codon M→I+s131-133TSM→NST...
2016: PloS One
Massimo Levrero, Jessica Zucman-Rossi
Hepatitis B virus (HBV) contributes to hepatocellular carcinoma (HCC) development through direct and indirect mechanisms. HBV DNA integration into the host genome occurs at early steps of clonal tumor expansion and induces both genomic instability and direct insertional mutagenesis of diverse cancer-related genes. Prolonged expression of the viral regulatory protein HBx and/or altered versions of the preS/S envelope proteins dysregulates cell transcription and proliferation control and sensitizes liver cells to carcinogenic factors...
April 2016: Journal of Hepatology
Shuping Tong, Peter Revill
Chronic infection with hepatitis B virus (HBV) greatly increases the risk for liver cirrhosis and hepatocellular carcinoma (HCC). HBV isolates worldwide can be divided into ten genotypes. Moreover, the immune clearance phase selects for mutations in different parts of the viral genome. The outcome of HBV infection is shaped by the complex interplay of the mode of transmission, host genetic factors, viral genotype and adaptive mutations, as well as environmental factors. Core promoter mutations and mutations abolishing hepatitis B e antigen (HBeAg) expression have been implicated in acute liver failure, while genotypes B, C, subgenotype A1, core promoter mutations, preS deletions, C-terminal truncation of envelope proteins, and spliced pregenomic RNA are associated with HCC development...
April 2016: Journal of Hepatology
An-Ye Zhang, Ching-Lung Lai, Ronnie Tung-Ping Poon, Fung-Yu Huang, Wai-Kay Seto, James Fung, Danny Ka-Ho Wong, Man-Fung Yuen
BACKGROUND AND AIM: Hepatitis B virus (HBV) full-length genomic mutations and quasispecies characteristics in hepatocellular carcinoma (HCC) were investigated. METHODS: Hepatitis B virus DNA was extracted from the tumor and non-tumor tissues of 16 HCC patients. Overlapping DNA fragments covering the entire HBV genome were amplified and sequenced. To study HBV sequence at the quasispecies level, the preS region was amplified and clonally sequenced. HBV mutation profiles, quasispecies complexity and diversity, and phylogenetic characteristics were assessed...
September 2016: Journal of Gastroenterology and Hepatology
Yong-Wei Li, Feng-Cai Yang, Hui-Qiong Lu, Jiong-Shan Zhang
The tumorigenesis of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) has been widely studied. HBV envelope proteins are important for the structure and life cycle of HBV, and these proteins are useful for judging the natural disease course and guiding treatment. Truncated and mutated preS/S are produced by integrated viral sequences that are defective for replication. The preS/S mutants are considered "precursor lesions" of HCC. Different preS/S mutants induce various mechanisms of tumorigenesis, such as transactivation of transcription factors and an immune inflammatory response, thereby contributing to HCC...
February 14, 2016: World Journal of Gastroenterology: WJG
Shinya Maekawa, Nobuyuki Enomoto
No abstract text is available yet for this article.
December 2015: Nihon Rinsho. Japanese Journal of Clinical Medicine
A Velay, H Jeulin, M Eschlimann, B Malvé, F Goehringer, M Bensenane, J-P Frippiat, P Abraham, A M Ismail, J M Murray, C Combet, F Zoulim, J-P Bronowicki, E Schvoerer
For hepatitis B virus (HBV)-related chronic infection under treatment by nucleos(t)ide analogues (NUCs), HBsAg clearance is the ultimate therapeutic goal but very infrequent. We investigated how HBV envelope protein variability could lead to differential HBsAg clearance on NUCs. For 12 HBV genotype D patients receiving NUCs, six resolvers (HBsAg clearance) were compared to six matched nonresolvers (HBsAg persistence). PreS/S amino acid (aa) sequences were analysed with bioinformatics to predict HBV envelope antigenicity and aa covariance...
May 2016: Journal of Viral Hepatitis
Mingzhen Jing, Jun Wang, Shengli Zhu, Fang Ao, Li Wang, Tao Han, Xin Yue, Ying Zhu, Linbai Ye, Shi Liu
BACKGROUND: Conventional hepatitis B virus (HBV) vaccines fail to induce protective antibody titers in 5-10% of immune-competent vaccinees. Therefore, there remains an urgent need to develop a safe and effective HBV vaccine. METHODS: In this study, we developed an effective and economical method for producing the HBV vaccine by using the high binding capacity of biotin-streptavidin. The preS antigen of HBV was fused with the core streptavidin (cSA) moiety (preS-cSA) and highly expressed in Escherichia coli...
January 20, 2016: Vaccine
Jang-June Park, David K Wong, Abdus S Wahed, William M Lee, Jordan J Feld, Norah Terrault, Mandana Khalili, Richard K Sterling, Kris V Kowdley, Natalie Bzowej, Daryl T Lau, W Ray Kim, Coleman Smith, Robert L Carithers, Keith W Torrey, James W Keith, Danielle L Levine, Daniel Traum, Suzanne Ho, Mary E Valiga, Geoffrey S Johnson, Edward Doo, Anna S F Lok, Kyong-Mi Chang
BACKGROUND & AIMS: T cells play a critical role in viral infection. We examined whether T-cell effector and regulatory responses can define clinical stages of chronic hepatitis B (CHB). METHODS: We enrolled 200 adults with CHB who participated in the National Institutes of Health-supported Hepatitis B Research Network from 2011 through 2013 and 20 uninfected individuals (controls). Peripheral blood lymphocytes from these subjects were analyzed for T-cell responses (proliferation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and lipopolysaccharide...
March 2016: Gastroenterology
Yang Yang, Jiang-Wei Sun, Long-Gang Zhao, Freddie Bray, Yong-Bing Xiang
BACKGROUND: The temporal relationship between hepatitis B virus (HBV) mutations and hepatocellular carcinoma (HCC) remains unclear. METHODS: We conducted a meta-analysis including cohort and nested case-control studies to prospectively examine the HCC risk associated with common variants of HBV in the PreS, Enhancer II, basal core promoter (BCP) and precore regions. Pertinent studies were identified by searching PubMed, Web of Science and the Chinese Biological Medicine databases through to November 2014...
October 2015: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
Opaleye O Oluyinka, Hoang Van Tong, Sy Bui Tien, Ademola H Fagbami, Olusegun Adekanle, Olusola Ojurongbe, C-Thomas Bock, Peter G Kremsner, Thirumalaisamy P Velavan
BACKGROUND: Occult hepatitis B virus infection (OBI) characterized by the absence of detectable HBsAg remains a potential threat in blood safety. We investigated the actual prevalence, viral factors and genotype of OBI infections in Nigerian blood donors. METHODS: Serum collected from two blood banks were reconfirmed as HBsAg seronegative by ELISA. Forty HBsAg positive samples were employed as controls. HBV-DNA was amplified from all donors and viral loads were determined using quantitative real-time PCR...
2015: PloS One
Riki Toita, Takahito Kawano, Jeong-Hun Kang, Masaharu Murata
Human hepatitis B virus (HBV) is a member of the family Hepadnaviridae, and causes acute and chronic infections of the liver. The hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins. The L protein consists of the S protein, preS1, and preS2. In HBsAg, the preS domain (preS1 + preS2) plays a key role in the infection of hepatocytic cells by HBV and has several immunogenic epitopes. Based on these characteristics of preS, several preS-based diagnostic and therapeutic materials and systems have been developed...
June 28, 2015: World Journal of Gastroenterology: WJG
Azira Muhamad, Kok Lian Ho, Mohd Basyaruddin Abdul Rahman, Bimo A Tejo, Dušan Uhrín, Wen Siang Tan
Hepatitis B virus (HBV) infection remains a health problem globally despite the availability of effective vaccines. In the assembly of the infectious virion, both the preS and S regions of the HBV large surface antigen (L-HBsAg) interact synergistically with the viral core antigen (HBcAg). Peptides preS and S based on the L-HBsAg were demonstrated as potential inhibitors to block the viral assembly. Therefore, the objectives of this study were to determine the solution structures of these peptides and study their interactions with HBcAg...
July 28, 2015: Organic & Biomolecular Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"